Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Chugai Pharmaceutical Co ( (JP:4519) ).
Chugai Pharmaceutical Co., Ltd., a key player in the pharmaceutical industry, is significantly influenced by its parent company, Roche Holding Ltd, which owns a majority of its shares. The recent announcement of Roche’s half-year results for 2025 includes Chugai’s performance, highlighting the integrated financial outcomes and strategic alignment between the two companies. This announcement underscores the operational synergy and market positioning of Chugai within the Roche Group, potentially impacting stakeholders by showcasing the company’s performance and strategic direction.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7650.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and marketing of innovative medicines. It is primarily engaged in the production of prescription drugs and is a significant player in the Japanese market. Chugai is a subsidiary of Roche Holding Ltd, which holds a majority stake in the company.
Average Trading Volume: 2,228,981
Technical Sentiment Signal: Buy
Current Market Cap: Yen11149.7B
See more data about 4519 stock on TipRanks’ Stock Analysis page.